CDA: Combinatorial drug discovery using transcriptional response modules

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Lee, Ji Hyun ^a   Kim, Dae Gyu ^a   Bae, Tae Jeong ^a   Rho, Kyoohyoung ^a   Kim, Ji Tae ^a   Lee, Jong Jun ^a   Jang, Yeongjun ^b   Kim, Byung Cheol ^a   Park, Kyoung Mii ^a   Kim, Sunghoon ^a  

^a Seoul National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ALSTERPAULLONE; DAUNORUBICIN; DIPYRONE; FULVESTRANT; HALOFANTRINE; IRINOTECAN; LETROZOLE; RETINOIC ACID; SEMUSTINE; TANESPIMYCIN; TRICHOSTATIN A; VERTEPORFIN; VINBLASTINE; VORINOSTAT;

ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; COMPUTER PROGRAM; DRUG DEVELOPMENT; DRUG POTENTIATION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; PHARMACOGENETICS; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINATORIAL CHEMISTRY TECHNIQUES; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MODELS, STATISTICAL; PHENANTHRENES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; VINBLASTINE;

EID: 84864698297     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042573     Document Type: Article

References (57)

1. Kubinyi H, (2003) Drug research: myths, hype and reality. Nat Rev Drug Discov 2: 665-668.
2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417.
3. Stelling J, Sauer U, Szallasi Z, Doyle FJ 3rd, Doyle J (2004) Robustness of cellular functions. Cell 118: 675-685.
4. Kitano H, (2007) A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 6: 202-210.
5. Gupta EK, Ito MK, (2002) Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia. Heart Dis 4: 124-137.
6. Larder BA, Kemp SD, Harrigan PR, (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699.
7. Nelson HS, (2001) Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. J Allergy Clin Immunol 107: 398-416.
8. Jia J, Zhu F, Ma X, Cao Z, Li Y, et al. (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8: 111-128.
9. Hahn CK, Ross KN, Warrington IM, Mazitschek R, Kanegai CM, et al. (2008) Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci U S A 105: 9751-9756.
10. Nelander S, Wang W, Nilsson B, She QB, Pratilas C, et al. (2008) Models from experiments: combinatorial drug perturbations of cancer cells. Mol Syst Biol 4: 216.
11. Chatterjee MS, Purvis JE, Brass LF, Diamond SL, (2010) Pairwise agonist scanning predicts cellular signaling responses to combinatorial stimuli. Nat Biotechnol 28: 727-732.
12. Zhao XM, Iskar M, Zeller G, Kuhn M, van Noort V, et al. (2011) Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput Biol 7: e1002323.
13. Wu Z, Zhao XM, Chen L, (2010) A systems biology approach to identify effective cocktail drugs. BMC Syst Biol 4 Suppl 2: S7.
14. Geva-Zatorsky N, Dekel E, Cohen AA, Danon T, Cohen L, et al. (2010) Protein dynamics in drug combinations: a linear superposition of individual-drug responses. Cell 140: 643-651.
15. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935.
16. Clemons M, Goss P, (2001) Estrogen and the risk of breast cancer. N Engl J Med 344: 276-285.
17. Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, et al. (2007) Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics 17: 813-826.
18. Croxtall JD, McKeage K, (2011) Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women. Drugs 71: 363-380.
19. Berx G, Van Roy F, (2001) The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 3: 289-293.
20. Oesterreich S, Deng W, Jiang S, Cui X, Ivanova M, et al. (2003) Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. Cancer Res 63: 5203-5208.
21. Hama K, Aoki J, Bandoh K, Inoue A, Endo T, et al. (2006) Lysophosphatidic receptor, LPA3, is positively and negatively regulated by progesterone and estrogen in the mouse uterus. Life Sci 79: 1736-1740.
22. Gonzalez-Arenas A, Avendano-Vazquez SE, Cabrera-Wrooman A, Tapia-Carrillo D, Larrea F, et al. (2008) Regulation of LPA receptor function by estrogens. Biochim Biophys Acta 1783: 253-262.
23. Contos JJ, Ishii I, Chun J, (2000) Lysophosphatidic acid receptors. Mol Pharmacol 58: 1188-1196.
24. Moolenaar WH, (1999) Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res 253: 230-238.
25. Stein T, Cosimo E, Yu X, Smith PR, Simon R, et al. (2010) Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. Am J Pathol 177: 2323-2333.
26. Lahusen T, De Siervi A, Kunick C, Senderowicz AM, (2003) Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase-9 due to perturbation in mitochondrial membrane potential. Mol Carcinog 36: 183-194.
27. Lee EJ, Lee BB, Kim SJ, Park YD, Park J, et al. (2008) Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells. Int J Oncol 33: 767-776.
28. Brazelle W, Kreahling JM, Gemmer J, Ma Y, Cress WD, et al. (2010) Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One 5: e14335.
29. Marsh S, Hoskins JM, (2010) Irinotecan pharmacogenomics. Pharmacogenomics 11: 1003-1010.
30. Guo Y, Lu JJ, Ma X, Wang B, Hong X, et al. (2008) Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy. Oral Oncol 44: 23-30.
31. Zhao Z, Liu Y, He H, Chen X, Chen J, et al. (2011) Candidate genes influencing sensitivity and resistance of human glioblastoma to Semustine. Brain Res Bull 86: 189-194.
32. Bange J, Zwick E, Ullrich A, (2001) Molecular targets for breast cancer therapy and prevention. Nat Med 7: 548-552.
33. Lo HW, Hsu SC, Hung MC, (2006) EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat 95: 211-218.
34. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, et al. (2009) Triple-negative breast cancer-current status and future directions. Ann Oncol 20: 1913-1927.
35. Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, et al. (2002) Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13: 65-72.
36. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, et al. (2001) Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61: 8887-8895.
37. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, et al. (2007) ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117: 2051-2058.
38. Bouchaud O, Imbert P, Touze JE, Dodoo AN, Danis M, et al. (2009) Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base. Malar J 8: 289.
39. Jordan MA, Wilson L, (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253-265.
40. Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, et al. (2011) HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Res Treat 130: 29-40.
41. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, et al. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320.
42. Weng C, Li Y, Xu D, Shi Y, Tang H, (2005) Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem 280: 10491-10500.
43. Ashburn TT, Thor KB, (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673-683.
44. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. (2009) Predicting new molecular targets for known drugs. Nature 462: 175-181.
45. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P, (2008) Drug target identification using side-effect similarity. Science 321: 263-266.
46. Hu G, Agarwal P, (2009) Human disease-drug network based on genomic expression profiles. PLoS One 4: e6536.
47. Hidalgo CA, Blumm N, Barabasi AL, Christakis NA, (2009) A dynamic network approach for the study of human phenotypes. PLoS Comput Biol 5: e1000353.
48. Yang L, Wang K, Chen J, Jegga AG, Luo H, et al. (2011) Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome-clozapine-induced agranulocytosis as a case study. PLoS Comput Biol 7: e1002016.
49. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, et al. (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5: 1136-1144.
50. Maglott D, Ostell J, Pruitt KD, Tatusova T, (2011) Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res 39: D52-57.
51. Ceol A, Chatr Aryamontri A, Licata L, Peluso D, Briganti L, et al. (2010) MINT, the molecular interaction database: 2009 update. Nucleic Acids Res 38: D532-539.
52. Salwinski L, Miller CS, Smith AJ, Pettit FK, Bowie JU, et al. (2004) The Database of Interacting Proteins: 2004 update. Nucleic Acids Res 32: D449-451.
53. Davis AP, King BL, Mockus S, Murphy CG, Saraceni-Richards C, et al. (2011) The Comparative Toxicogenomics Database: update 2011. Nucleic Acids Res 39: D1067-1072.
54. Zhu F, Han B, Kumar P, Liu X, Ma X, et al. (2010) Update of TTD: Therapeutic Target Database. Nucleic Acids Res 38: D787-791.
55. Seiler KP, George GA, Happ MP, Bodycombe NE, Carrinski HA, et al. (2008) ChemBank: a small-molecule screening and cheminformatics resource database. Nucleic Acids Res 36: D351-359.
56. Thorn CF, Klein TE, Altman RB, (2010) Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics 11: 501-505.
57. Becker KG, Barnes KC, Bright TJ, Wang SA, (2004) The genetic association database. Nat Genet 36: 431-432.